Drug Development · us
Inhibiting Two Lipid Targets at Once: Dual-Function RNA Therapy Reports First Human Results
A Phase 1 trial in 31 participants showed reductions in both low-density lipoprotein cholesterol and triglycerides after a single dose of ARO-DIMER-PA; whether it can sustain lipid control and reduce cardiovascular events remains to be verified.
Elevated cholesterol and triglycerides often require lipid treatment to address different pathways. A first-in-human trial now offers an early indication that a single RNA drug may lower both types of blood lipids, though demonstrating long-term clinical benefits remains some way off.
Cleveland Clinic announced on November 7 that ARO-DIMER-PA, developed by Arrowhead, showed lipid-lowering effects in a Phase 1 trial involving 31 participants. The single ascending-dose portion of this randomized, double-blind, placebo-controlled study tested five doses ranging from 25 to 400 milligrams; the results were presented at the American Heart Association Scientific Sessions.
ARO-DIMER-PA is a small interfering RNA (siRNA) designed to inhibit two targets in the liver simultaneously: PCSK9 and APOC3. The study aims to combine lipid pathways that have previously been addressed separately into a single-drug strategy.
According to the announcement, low-density lipoprotein cholesterol (LDL-C) fell by 26% to 65%, while triglycerides fell by 56% to 78%, with larger reductions at higher doses. However, the announcement did not specify the assessment time points for these figures or how placebo adjustment was performed. These information gaps must be kept in mind when interpreting the results.
Regarding safety, the research team reported that the treatment was generally well tolerated, with injection-site redness the most common adverse reaction; more side effects occurred at the highest dose of 400 milligrams. Results from a small, single-dose study are not sufficient to establish the safety of repeated use or long-term treatment.
Another multiple-dose study is underway and will help clarify dose selection for subsequent trials. Whether reductions in blood lipid levels translate into fewer heart attacks or strokes remains a question for cardiovascular outcomes studies. This study was funded by Arrowhead.